Cue Biopharma (NASDAQ:CUE) has dosed the first patient in a Phase 1 dose escalation study evaluating CUE-102 for the treatment of patients with Wilms’ Tumor 1 (WT1)-positive recurrent/metastatic cancers.
The Phase 1 dose escalation and expansion study will evaluate the safety, tolerability, anti-tumor activity, and immunogenicity of CUE-102 in HLA-A*0201 positive subjects with WT1-positive recurrent/metastatic cancers.
The study is designed to enroll approximately 50 patients.
CUE-102 is Cue Biopharma’s second clinical drug candidate from the CUE-100 series of interleukin 2 (IL-2)-based biologics.
Dan Passeri, Chief executive officer, commented: “Initiating this Phase 1 clinical study of CUE-102 at a starting dose of 1mg/kg, a clinically active dose in our Phase 1 CUE-101 clinical trial for HPV+ head and neck cancer, is an important step forward in demonstrating the modularity of our Immuno-STAT™ platform and the broader clinical potential of our CUE-100 series of biologics.”
The Phase 1 dose escalation study will initially focus on colorectal, gastric, pancreatic, and ovarian cancers.
Price Action : Cue Biopharma shares are trading around 7 percent down at $2.85 on Monday at the time of publication.
